Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 15, 2024Journal of Bone and Mineral MetabolismOpen Access

Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis

View Full Paper
Ask AI
Bookmark
Share

Authors

KEKosuke EbinaOsaka City UniversityYEYuki EtaniThe University of OsakaTNTakaaki NoguchiThe University of Osaka

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ebina et al. (2024) studied this question.

synapsesocial.com/papers/6a0065c02ff633f36577ec09https://doi.org/10.1007/s00774-024-01536-0
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Romosozumab in Postmenopausal Women with Low Bone Mineral Density2014 · 1,265 citations
  2. 2Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling2015 · 306 citations
  3. 3Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis2001 · 4,617 citations
  4. 4Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study2022 · 44 citations